Stimuli-responsive ultra-small vanadate prodrug nanoparticles with NIR photothermal properties to precisely inhibit Na/K-ATPase for enhanced cancer therapy.

Abstract

Inhibition of Na/K-ATPase is a promising cancer treatment owing to the essential role of Na/K-ATPase in maintaining various cellular functions. The potent Na/K-ATPase inhibitor, vanadate(V) (termed as V(V)), has exhibited efficient anticancer effects. However, nonspecific inhibition using V(V) results in serious side effects, which hinder its clinical application. Here, bovine serum albumin (BSA)-modified ultra-small vanadate prodrug nanoparticles (V(IV) NPs) were synthesized via a combined reduction-coordination strategy with a natural polyphenol tannic acid (TA). A lower systemic toxicity of V(IV) NPs is achieved by strong metal-polyphenol coordination interactions. An efficient V(V) activation is realized by reactive oxygen species (ROS) at the tumor site. Furthermore, V(IV) NPs show excellent photothermal properties in the near-infrared (NIR) region. By NIR irradiation at the tumor site for mild hyperthermia, selective enhancement of the interactions between V(V) and Na/K-ATPase achieves stronger inhibition of Na/K-ATPase for robust cell killing effect. Altogether, V(IV) NPs specifically inhibit Na/K-ATPase in cancer cells with negligible toxicity to normal tissues, thus making them a promising candidate for clinical applications of Na/K-ATPase inhibition.